Global Ocaliva Market

Ocaliva Comprehensive Study by Application (Primary Biliary Cirrhosis, Non-alcoholic Fatty Liver Disease, Other), Distribution Channel (Online, Offline), End-User (Hospitals, Cancer Centres, Others), Strength (5 mg, 10 mg) Players and Region - Global Market Outlook to 2026

Ocaliva Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Ocaliva Market Scope?
Ocaliva is used to treat adults with a disease called primary biliary cholangitis. Primary biliary cholangitis is an autoimmune condition during which there's the gradual destruction of the tiny gall ducts within the liver. These ducts transport fluid referred to as gall from the liver to the intestines, wherever it's used to help digest fats. As a result of the injury to the ducts, gall builds up within the liver inflicting injury to the liver tissue. This might result in scarring and liver failure and will increase the danger of liver cancer. Ocaliva contains the active substance obeticholic acid. It's used together with another medication, ursodeoxycholic acid (UDCA), in patients who don't respond sufficiently to UDCA alone, and on its own in patients who cannot take UDCA. Primary biliary cholangitis is rare, and Ocaliva was designated an ‘orphan medicine’ (a medicine utilized in rare diseases) on 27 July 2010.

The Ocaliva market study is being classified, by Application (Primary Biliary Cirrhosis, Non-alcoholic Fatty Liver Disease and Other) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from Asian will contribute to the maximum growth of Global Ocaliva market throughout the predicted period.

Dr. Reddy's Laboratories (India), Intercept Pharmaceuticals (United States), Dainippon Sumitomo Pharma (Japan), Biophore India Pharmaceuticals Pvt (India), Summit Pharmaceuticals (Japan), Optimus Pharma P Limited (India), Alembic Pharmaceuticals Limited (India), MSN Laboratories Pvt Ltd (India), Sichuan Xieli Pharmaceutical (China), Changzhou Pharmaceutical Factory (China) and Omgene Life Sciences (India) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Ocaliva market by Type, Application and Region.

On the basis of geography, the market of Ocaliva has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Rise in The Recommendation for The Drug from The Doctors

Market Drivers
  • Increase in The Geriatric Population
  • Increase in the Cases of Primary Biliary Cholangitis

Opportunities
  • Increased Research for The Drug
  • Increase in Investment by The Key Players

Restraints
  • Side- Effects of The Drug
  • High Cost of The Drug

Challenges
  • Lack of Awareness of The Drug


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Ocaliva, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Primary Biliary Cirrhosis
  • Non-alcoholic Fatty Liver Disease
  • Other
By Distribution Channel
  • Online
  • Offline

By End-User
  • Hospitals
  • Cancer Centres
  • Others

By Strength
  • 5 mg
  • 10 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in The Geriatric Population
      • 3.2.2. Increase in the Cases of Primary Biliary Cholangitis
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of The Drug
    • 3.4. Market Trends
      • 3.4.1. Rise in The Recommendation for The Drug from The Doctors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ocaliva, by Application, Distribution Channel, End-User, Strength and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ocaliva (Value)
      • 5.2.1. Global Ocaliva by: Application (Value)
        • 5.2.1.1. Primary Biliary Cirrhosis
        • 5.2.1.2. Non-alcoholic Fatty Liver Disease
        • 5.2.1.3. Other
      • 5.2.2. Global Ocaliva by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Offline
      • 5.2.3. Global Ocaliva by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Centres
        • 5.2.3.3. Others
      • 5.2.4. Global Ocaliva by: Strength (Value)
        • 5.2.4.1. 5 mg
        • 5.2.4.2. 10 mg
      • 5.2.5. Global Ocaliva Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Ocaliva (Volume)
      • 5.3.1. Global Ocaliva by: Application (Volume)
        • 5.3.1.1. Primary Biliary Cirrhosis
        • 5.3.1.2. Non-alcoholic Fatty Liver Disease
        • 5.3.1.3. Other
      • 5.3.2. Global Ocaliva by: Distribution Channel (Volume)
        • 5.3.2.1. Online
        • 5.3.2.2. Offline
      • 5.3.3. Global Ocaliva by: End-User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Cancer Centres
        • 5.3.3.3. Others
      • 5.3.4. Global Ocaliva by: Strength (Volume)
        • 5.3.4.1. 5 mg
        • 5.3.4.2. 10 mg
      • 5.3.5. Global Ocaliva Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Ocaliva (Price)
  • 6. Ocaliva: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dr. Reddy's Laboratories (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Intercept Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dainippon Sumitomo Pharma (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biophore India Pharmaceuticals Pvt (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Summit Pharmaceuticals (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Optimus Pharma P Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alembic Pharmaceuticals Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MSN Laboratories Pvt Ltd (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sichuan Xieli Pharmaceutical (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Changzhou Pharmaceutical Factory (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Omgene Life Sciences (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Ocaliva Sale, by Application, Distribution Channel, End-User, Strength and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ocaliva (Value)
      • 7.2.1. Global Ocaliva by: Application (Value)
        • 7.2.1.1. Primary Biliary Cirrhosis
        • 7.2.1.2. Non-alcoholic Fatty Liver Disease
        • 7.2.1.3. Other
      • 7.2.2. Global Ocaliva by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Offline
      • 7.2.3. Global Ocaliva by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Centres
        • 7.2.3.3. Others
      • 7.2.4. Global Ocaliva by: Strength (Value)
        • 7.2.4.1. 5 mg
        • 7.2.4.2. 10 mg
      • 7.2.5. Global Ocaliva Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Ocaliva (Volume)
      • 7.3.1. Global Ocaliva by: Application (Volume)
        • 7.3.1.1. Primary Biliary Cirrhosis
        • 7.3.1.2. Non-alcoholic Fatty Liver Disease
        • 7.3.1.3. Other
      • 7.3.2. Global Ocaliva by: Distribution Channel (Volume)
        • 7.3.2.1. Online
        • 7.3.2.2. Offline
      • 7.3.3. Global Ocaliva by: End-User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Cancer Centres
        • 7.3.3.3. Others
      • 7.3.4. Global Ocaliva by: Strength (Volume)
        • 7.3.4.1. 5 mg
        • 7.3.4.2. 10 mg
      • 7.3.5. Global Ocaliva Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Ocaliva (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ocaliva: by Application(USD Million)
  • Table 2. Ocaliva Primary Biliary Cirrhosis , by Region USD Million (2015-2020)
  • Table 3. Ocaliva Non-alcoholic Fatty Liver Disease , by Region USD Million (2015-2020)
  • Table 4. Ocaliva Other , by Region USD Million (2015-2020)
  • Table 5. Ocaliva: by Distribution Channel(USD Million)
  • Table 6. Ocaliva Online , by Region USD Million (2015-2020)
  • Table 7. Ocaliva Offline , by Region USD Million (2015-2020)
  • Table 8. Ocaliva: by End-User(USD Million)
  • Table 9. Ocaliva Hospitals , by Region USD Million (2015-2020)
  • Table 10. Ocaliva Cancer Centres , by Region USD Million (2015-2020)
  • Table 11. Ocaliva Others , by Region USD Million (2015-2020)
  • Table 12. Ocaliva: by Strength(USD Million)
  • Table 13. Ocaliva 5 mg , by Region USD Million (2015-2020)
  • Table 14. Ocaliva 10 mg , by Region USD Million (2015-2020)
  • Table 15. South America Ocaliva, by Country USD Million (2015-2020)
  • Table 16. South America Ocaliva, by Application USD Million (2015-2020)
  • Table 17. South America Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 18. South America Ocaliva, by End-User USD Million (2015-2020)
  • Table 19. South America Ocaliva, by Strength USD Million (2015-2020)
  • Table 20. Brazil Ocaliva, by Application USD Million (2015-2020)
  • Table 21. Brazil Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil Ocaliva, by End-User USD Million (2015-2020)
  • Table 23. Brazil Ocaliva, by Strength USD Million (2015-2020)
  • Table 24. Argentina Ocaliva, by Application USD Million (2015-2020)
  • Table 25. Argentina Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 26. Argentina Ocaliva, by End-User USD Million (2015-2020)
  • Table 27. Argentina Ocaliva, by Strength USD Million (2015-2020)
  • Table 28. Rest of South America Ocaliva, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 30. Rest of South America Ocaliva, by End-User USD Million (2015-2020)
  • Table 31. Rest of South America Ocaliva, by Strength USD Million (2015-2020)
  • Table 32. Asia Pacific Ocaliva, by Country USD Million (2015-2020)
  • Table 33. Asia Pacific Ocaliva, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 35. Asia Pacific Ocaliva, by End-User USD Million (2015-2020)
  • Table 36. Asia Pacific Ocaliva, by Strength USD Million (2015-2020)
  • Table 37. China Ocaliva, by Application USD Million (2015-2020)
  • Table 38. China Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 39. China Ocaliva, by End-User USD Million (2015-2020)
  • Table 40. China Ocaliva, by Strength USD Million (2015-2020)
  • Table 41. Japan Ocaliva, by Application USD Million (2015-2020)
  • Table 42. Japan Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 43. Japan Ocaliva, by End-User USD Million (2015-2020)
  • Table 44. Japan Ocaliva, by Strength USD Million (2015-2020)
  • Table 45. India Ocaliva, by Application USD Million (2015-2020)
  • Table 46. India Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 47. India Ocaliva, by End-User USD Million (2015-2020)
  • Table 48. India Ocaliva, by Strength USD Million (2015-2020)
  • Table 49. South Korea Ocaliva, by Application USD Million (2015-2020)
  • Table 50. South Korea Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 51. South Korea Ocaliva, by End-User USD Million (2015-2020)
  • Table 52. South Korea Ocaliva, by Strength USD Million (2015-2020)
  • Table 53. Taiwan Ocaliva, by Application USD Million (2015-2020)
  • Table 54. Taiwan Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 55. Taiwan Ocaliva, by End-User USD Million (2015-2020)
  • Table 56. Taiwan Ocaliva, by Strength USD Million (2015-2020)
  • Table 57. Australia Ocaliva, by Application USD Million (2015-2020)
  • Table 58. Australia Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 59. Australia Ocaliva, by End-User USD Million (2015-2020)
  • Table 60. Australia Ocaliva, by Strength USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Ocaliva, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Ocaliva, by End-User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Ocaliva, by Strength USD Million (2015-2020)
  • Table 65. Europe Ocaliva, by Country USD Million (2015-2020)
  • Table 66. Europe Ocaliva, by Application USD Million (2015-2020)
  • Table 67. Europe Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 68. Europe Ocaliva, by End-User USD Million (2015-2020)
  • Table 69. Europe Ocaliva, by Strength USD Million (2015-2020)
  • Table 70. Germany Ocaliva, by Application USD Million (2015-2020)
  • Table 71. Germany Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 72. Germany Ocaliva, by End-User USD Million (2015-2020)
  • Table 73. Germany Ocaliva, by Strength USD Million (2015-2020)
  • Table 74. France Ocaliva, by Application USD Million (2015-2020)
  • Table 75. France Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 76. France Ocaliva, by End-User USD Million (2015-2020)
  • Table 77. France Ocaliva, by Strength USD Million (2015-2020)
  • Table 78. Italy Ocaliva, by Application USD Million (2015-2020)
  • Table 79. Italy Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 80. Italy Ocaliva, by End-User USD Million (2015-2020)
  • Table 81. Italy Ocaliva, by Strength USD Million (2015-2020)
  • Table 82. United Kingdom Ocaliva, by Application USD Million (2015-2020)
  • Table 83. United Kingdom Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 84. United Kingdom Ocaliva, by End-User USD Million (2015-2020)
  • Table 85. United Kingdom Ocaliva, by Strength USD Million (2015-2020)
  • Table 86. Netherlands Ocaliva, by Application USD Million (2015-2020)
  • Table 87. Netherlands Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 88. Netherlands Ocaliva, by End-User USD Million (2015-2020)
  • Table 89. Netherlands Ocaliva, by Strength USD Million (2015-2020)
  • Table 90. Rest of Europe Ocaliva, by Application USD Million (2015-2020)
  • Table 91. Rest of Europe Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 92. Rest of Europe Ocaliva, by End-User USD Million (2015-2020)
  • Table 93. Rest of Europe Ocaliva, by Strength USD Million (2015-2020)
  • Table 94. MEA Ocaliva, by Country USD Million (2015-2020)
  • Table 95. MEA Ocaliva, by Application USD Million (2015-2020)
  • Table 96. MEA Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 97. MEA Ocaliva, by End-User USD Million (2015-2020)
  • Table 98. MEA Ocaliva, by Strength USD Million (2015-2020)
  • Table 99. Middle East Ocaliva, by Application USD Million (2015-2020)
  • Table 100. Middle East Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 101. Middle East Ocaliva, by End-User USD Million (2015-2020)
  • Table 102. Middle East Ocaliva, by Strength USD Million (2015-2020)
  • Table 103. Africa Ocaliva, by Application USD Million (2015-2020)
  • Table 104. Africa Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 105. Africa Ocaliva, by End-User USD Million (2015-2020)
  • Table 106. Africa Ocaliva, by Strength USD Million (2015-2020)
  • Table 107. North America Ocaliva, by Country USD Million (2015-2020)
  • Table 108. North America Ocaliva, by Application USD Million (2015-2020)
  • Table 109. North America Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 110. North America Ocaliva, by End-User USD Million (2015-2020)
  • Table 111. North America Ocaliva, by Strength USD Million (2015-2020)
  • Table 112. United States Ocaliva, by Application USD Million (2015-2020)
  • Table 113. United States Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 114. United States Ocaliva, by End-User USD Million (2015-2020)
  • Table 115. United States Ocaliva, by Strength USD Million (2015-2020)
  • Table 116. Canada Ocaliva, by Application USD Million (2015-2020)
  • Table 117. Canada Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 118. Canada Ocaliva, by End-User USD Million (2015-2020)
  • Table 119. Canada Ocaliva, by Strength USD Million (2015-2020)
  • Table 120. Mexico Ocaliva, by Application USD Million (2015-2020)
  • Table 121. Mexico Ocaliva, by Distribution Channel USD Million (2015-2020)
  • Table 122. Mexico Ocaliva, by End-User USD Million (2015-2020)
  • Table 123. Mexico Ocaliva, by Strength USD Million (2015-2020)
  • Table 124. Ocaliva Sales: by Application(K Tons)
  • Table 125. Ocaliva Sales Primary Biliary Cirrhosis , by Region K Tons (2015-2020)
  • Table 126. Ocaliva Sales Non-alcoholic Fatty Liver Disease , by Region K Tons (2015-2020)
  • Table 127. Ocaliva Sales Other , by Region K Tons (2015-2020)
  • Table 128. Ocaliva Sales: by Distribution Channel(K Tons)
  • Table 129. Ocaliva Sales Online , by Region K Tons (2015-2020)
  • Table 130. Ocaliva Sales Offline , by Region K Tons (2015-2020)
  • Table 131. Ocaliva Sales: by End-User(K Tons)
  • Table 132. Ocaliva Sales Hospitals , by Region K Tons (2015-2020)
  • Table 133. Ocaliva Sales Cancer Centres , by Region K Tons (2015-2020)
  • Table 134. Ocaliva Sales Others , by Region K Tons (2015-2020)
  • Table 135. Ocaliva Sales: by Strength(K Tons)
  • Table 136. Ocaliva Sales 5 mg , by Region K Tons (2015-2020)
  • Table 137. Ocaliva Sales 10 mg , by Region K Tons (2015-2020)
  • Table 138. South America Ocaliva Sales, by Country K Tons (2015-2020)
  • Table 139. South America Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 140. South America Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 141. South America Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 142. South America Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 143. Brazil Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 144. Brazil Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 145. Brazil Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 146. Brazil Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 147. Argentina Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 148. Argentina Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 149. Argentina Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 150. Argentina Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 151. Rest of South America Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 152. Rest of South America Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 153. Rest of South America Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 154. Rest of South America Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 155. Asia Pacific Ocaliva Sales, by Country K Tons (2015-2020)
  • Table 156. Asia Pacific Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 157. Asia Pacific Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 158. Asia Pacific Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 159. Asia Pacific Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 160. China Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 161. China Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 162. China Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 163. China Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 164. Japan Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 165. Japan Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 166. Japan Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 167. Japan Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 168. India Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 169. India Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 170. India Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 171. India Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 172. South Korea Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 173. South Korea Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 174. South Korea Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 175. South Korea Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 176. Taiwan Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 177. Taiwan Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 178. Taiwan Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 179. Taiwan Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 180. Australia Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 181. Australia Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 182. Australia Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 183. Australia Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 184. Rest of Asia-Pacific Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 185. Rest of Asia-Pacific Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 186. Rest of Asia-Pacific Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 187. Rest of Asia-Pacific Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 188. Europe Ocaliva Sales, by Country K Tons (2015-2020)
  • Table 189. Europe Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 190. Europe Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 191. Europe Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 192. Europe Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 193. Germany Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 194. Germany Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 195. Germany Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 196. Germany Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 197. France Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 198. France Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. France Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 200. France Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 201. Italy Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 202. Italy Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 203. Italy Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 204. Italy Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 205. United Kingdom Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 206. United Kingdom Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 207. United Kingdom Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 208. United Kingdom Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 209. Netherlands Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 210. Netherlands Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 211. Netherlands Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 212. Netherlands Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 213. Rest of Europe Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 214. Rest of Europe Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 215. Rest of Europe Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 216. Rest of Europe Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 217. MEA Ocaliva Sales, by Country K Tons (2015-2020)
  • Table 218. MEA Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 219. MEA Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 220. MEA Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 221. MEA Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 222. Middle East Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 223. Middle East Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 224. Middle East Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 225. Middle East Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 226. Africa Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 227. Africa Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 228. Africa Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 229. Africa Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 230. North America Ocaliva Sales, by Country K Tons (2015-2020)
  • Table 231. North America Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 232. North America Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 233. North America Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 234. North America Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 235. United States Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 236. United States Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 237. United States Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 238. United States Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 239. Canada Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 240. Canada Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 241. Canada Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 242. Canada Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 243. Mexico Ocaliva Sales, by Application K Tons (2015-2020)
  • Table 244. Mexico Ocaliva Sales, by Distribution Channel K Tons (2015-2020)
  • Table 245. Mexico Ocaliva Sales, by End-User K Tons (2015-2020)
  • Table 246. Mexico Ocaliva Sales, by Strength K Tons (2015-2020)
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Ocaliva: by Application(USD Million)
  • Table 259. Ocaliva Primary Biliary Cirrhosis , by Region USD Million (2021-2026)
  • Table 260. Ocaliva Non-alcoholic Fatty Liver Disease , by Region USD Million (2021-2026)
  • Table 261. Ocaliva Other , by Region USD Million (2021-2026)
  • Table 262. Ocaliva: by Distribution Channel(USD Million)
  • Table 263. Ocaliva Online , by Region USD Million (2021-2026)
  • Table 264. Ocaliva Offline , by Region USD Million (2021-2026)
  • Table 265. Ocaliva: by End-User(USD Million)
  • Table 266. Ocaliva Hospitals , by Region USD Million (2021-2026)
  • Table 267. Ocaliva Cancer Centres , by Region USD Million (2021-2026)
  • Table 268. Ocaliva Others , by Region USD Million (2021-2026)
  • Table 269. Ocaliva: by Strength(USD Million)
  • Table 270. Ocaliva 5 mg , by Region USD Million (2021-2026)
  • Table 271. Ocaliva 10 mg , by Region USD Million (2021-2026)
  • Table 272. South America Ocaliva, by Country USD Million (2021-2026)
  • Table 273. South America Ocaliva, by Application USD Million (2021-2026)
  • Table 274. South America Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 275. South America Ocaliva, by End-User USD Million (2021-2026)
  • Table 276. South America Ocaliva, by Strength USD Million (2021-2026)
  • Table 277. Brazil Ocaliva, by Application USD Million (2021-2026)
  • Table 278. Brazil Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 279. Brazil Ocaliva, by End-User USD Million (2021-2026)
  • Table 280. Brazil Ocaliva, by Strength USD Million (2021-2026)
  • Table 281. Argentina Ocaliva, by Application USD Million (2021-2026)
  • Table 282. Argentina Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 283. Argentina Ocaliva, by End-User USD Million (2021-2026)
  • Table 284. Argentina Ocaliva, by Strength USD Million (2021-2026)
  • Table 285. Rest of South America Ocaliva, by Application USD Million (2021-2026)
  • Table 286. Rest of South America Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 287. Rest of South America Ocaliva, by End-User USD Million (2021-2026)
  • Table 288. Rest of South America Ocaliva, by Strength USD Million (2021-2026)
  • Table 289. Asia Pacific Ocaliva, by Country USD Million (2021-2026)
  • Table 290. Asia Pacific Ocaliva, by Application USD Million (2021-2026)
  • Table 291. Asia Pacific Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 292. Asia Pacific Ocaliva, by End-User USD Million (2021-2026)
  • Table 293. Asia Pacific Ocaliva, by Strength USD Million (2021-2026)
  • Table 294. China Ocaliva, by Application USD Million (2021-2026)
  • Table 295. China Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 296. China Ocaliva, by End-User USD Million (2021-2026)
  • Table 297. China Ocaliva, by Strength USD Million (2021-2026)
  • Table 298. Japan Ocaliva, by Application USD Million (2021-2026)
  • Table 299. Japan Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 300. Japan Ocaliva, by End-User USD Million (2021-2026)
  • Table 301. Japan Ocaliva, by Strength USD Million (2021-2026)
  • Table 302. India Ocaliva, by Application USD Million (2021-2026)
  • Table 303. India Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 304. India Ocaliva, by End-User USD Million (2021-2026)
  • Table 305. India Ocaliva, by Strength USD Million (2021-2026)
  • Table 306. South Korea Ocaliva, by Application USD Million (2021-2026)
  • Table 307. South Korea Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 308. South Korea Ocaliva, by End-User USD Million (2021-2026)
  • Table 309. South Korea Ocaliva, by Strength USD Million (2021-2026)
  • Table 310. Taiwan Ocaliva, by Application USD Million (2021-2026)
  • Table 311. Taiwan Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 312. Taiwan Ocaliva, by End-User USD Million (2021-2026)
  • Table 313. Taiwan Ocaliva, by Strength USD Million (2021-2026)
  • Table 314. Australia Ocaliva, by Application USD Million (2021-2026)
  • Table 315. Australia Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 316. Australia Ocaliva, by End-User USD Million (2021-2026)
  • Table 317. Australia Ocaliva, by Strength USD Million (2021-2026)
  • Table 318. Rest of Asia-Pacific Ocaliva, by Application USD Million (2021-2026)
  • Table 319. Rest of Asia-Pacific Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 320. Rest of Asia-Pacific Ocaliva, by End-User USD Million (2021-2026)
  • Table 321. Rest of Asia-Pacific Ocaliva, by Strength USD Million (2021-2026)
  • Table 322. Europe Ocaliva, by Country USD Million (2021-2026)
  • Table 323. Europe Ocaliva, by Application USD Million (2021-2026)
  • Table 324. Europe Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 325. Europe Ocaliva, by End-User USD Million (2021-2026)
  • Table 326. Europe Ocaliva, by Strength USD Million (2021-2026)
  • Table 327. Germany Ocaliva, by Application USD Million (2021-2026)
  • Table 328. Germany Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 329. Germany Ocaliva, by End-User USD Million (2021-2026)
  • Table 330. Germany Ocaliva, by Strength USD Million (2021-2026)
  • Table 331. France Ocaliva, by Application USD Million (2021-2026)
  • Table 332. France Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 333. France Ocaliva, by End-User USD Million (2021-2026)
  • Table 334. France Ocaliva, by Strength USD Million (2021-2026)
  • Table 335. Italy Ocaliva, by Application USD Million (2021-2026)
  • Table 336. Italy Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 337. Italy Ocaliva, by End-User USD Million (2021-2026)
  • Table 338. Italy Ocaliva, by Strength USD Million (2021-2026)
  • Table 339. United Kingdom Ocaliva, by Application USD Million (2021-2026)
  • Table 340. United Kingdom Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 341. United Kingdom Ocaliva, by End-User USD Million (2021-2026)
  • Table 342. United Kingdom Ocaliva, by Strength USD Million (2021-2026)
  • Table 343. Netherlands Ocaliva, by Application USD Million (2021-2026)
  • Table 344. Netherlands Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 345. Netherlands Ocaliva, by End-User USD Million (2021-2026)
  • Table 346. Netherlands Ocaliva, by Strength USD Million (2021-2026)
  • Table 347. Rest of Europe Ocaliva, by Application USD Million (2021-2026)
  • Table 348. Rest of Europe Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 349. Rest of Europe Ocaliva, by End-User USD Million (2021-2026)
  • Table 350. Rest of Europe Ocaliva, by Strength USD Million (2021-2026)
  • Table 351. MEA Ocaliva, by Country USD Million (2021-2026)
  • Table 352. MEA Ocaliva, by Application USD Million (2021-2026)
  • Table 353. MEA Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 354. MEA Ocaliva, by End-User USD Million (2021-2026)
  • Table 355. MEA Ocaliva, by Strength USD Million (2021-2026)
  • Table 356. Middle East Ocaliva, by Application USD Million (2021-2026)
  • Table 357. Middle East Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 358. Middle East Ocaliva, by End-User USD Million (2021-2026)
  • Table 359. Middle East Ocaliva, by Strength USD Million (2021-2026)
  • Table 360. Africa Ocaliva, by Application USD Million (2021-2026)
  • Table 361. Africa Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 362. Africa Ocaliva, by End-User USD Million (2021-2026)
  • Table 363. Africa Ocaliva, by Strength USD Million (2021-2026)
  • Table 364. North America Ocaliva, by Country USD Million (2021-2026)
  • Table 365. North America Ocaliva, by Application USD Million (2021-2026)
  • Table 366. North America Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 367. North America Ocaliva, by End-User USD Million (2021-2026)
  • Table 368. North America Ocaliva, by Strength USD Million (2021-2026)
  • Table 369. United States Ocaliva, by Application USD Million (2021-2026)
  • Table 370. United States Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 371. United States Ocaliva, by End-User USD Million (2021-2026)
  • Table 372. United States Ocaliva, by Strength USD Million (2021-2026)
  • Table 373. Canada Ocaliva, by Application USD Million (2021-2026)
  • Table 374. Canada Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 375. Canada Ocaliva, by End-User USD Million (2021-2026)
  • Table 376. Canada Ocaliva, by Strength USD Million (2021-2026)
  • Table 377. Mexico Ocaliva, by Application USD Million (2021-2026)
  • Table 378. Mexico Ocaliva, by Distribution Channel USD Million (2021-2026)
  • Table 379. Mexico Ocaliva, by End-User USD Million (2021-2026)
  • Table 380. Mexico Ocaliva, by Strength USD Million (2021-2026)
  • Table 381. Ocaliva Sales: by Application(K Tons)
  • Table 382. Ocaliva Sales Primary Biliary Cirrhosis , by Region K Tons (2021-2026)
  • Table 383. Ocaliva Sales Non-alcoholic Fatty Liver Disease , by Region K Tons (2021-2026)
  • Table 384. Ocaliva Sales Other , by Region K Tons (2021-2026)
  • Table 385. Ocaliva Sales: by Distribution Channel(K Tons)
  • Table 386. Ocaliva Sales Online , by Region K Tons (2021-2026)
  • Table 387. Ocaliva Sales Offline , by Region K Tons (2021-2026)
  • Table 388. Ocaliva Sales: by End-User(K Tons)
  • Table 389. Ocaliva Sales Hospitals , by Region K Tons (2021-2026)
  • Table 390. Ocaliva Sales Cancer Centres , by Region K Tons (2021-2026)
  • Table 391. Ocaliva Sales Others , by Region K Tons (2021-2026)
  • Table 392. Ocaliva Sales: by Strength(K Tons)
  • Table 393. Ocaliva Sales 5 mg , by Region K Tons (2021-2026)
  • Table 394. Ocaliva Sales 10 mg , by Region K Tons (2021-2026)
  • Table 395. South America Ocaliva Sales, by Country K Tons (2021-2026)
  • Table 396. South America Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 397. South America Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 398. South America Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 399. South America Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 400. Brazil Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 401. Brazil Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 402. Brazil Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 403. Brazil Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 404. Argentina Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 405. Argentina Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 406. Argentina Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 407. Argentina Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 408. Rest of South America Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 409. Rest of South America Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 410. Rest of South America Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 411. Rest of South America Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 412. Asia Pacific Ocaliva Sales, by Country K Tons (2021-2026)
  • Table 413. Asia Pacific Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 414. Asia Pacific Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 415. Asia Pacific Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 416. Asia Pacific Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 417. China Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 418. China Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 419. China Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 420. China Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 421. Japan Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 422. Japan Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 423. Japan Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 424. Japan Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 425. India Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 426. India Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 427. India Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 428. India Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 429. South Korea Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 430. South Korea Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 431. South Korea Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 432. South Korea Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 433. Taiwan Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 434. Taiwan Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 435. Taiwan Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 436. Taiwan Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 437. Australia Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 438. Australia Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 439. Australia Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 440. Australia Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 441. Rest of Asia-Pacific Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 442. Rest of Asia-Pacific Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 443. Rest of Asia-Pacific Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 444. Rest of Asia-Pacific Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 445. Europe Ocaliva Sales, by Country K Tons (2021-2026)
  • Table 446. Europe Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 447. Europe Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 448. Europe Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 449. Europe Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 450. Germany Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 451. Germany Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 452. Germany Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 453. Germany Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 454. France Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 455. France Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 456. France Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 457. France Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 458. Italy Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 459. Italy Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 460. Italy Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 461. Italy Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 462. United Kingdom Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 463. United Kingdom Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 464. United Kingdom Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 465. United Kingdom Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 466. Netherlands Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 467. Netherlands Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 468. Netherlands Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 469. Netherlands Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 470. Rest of Europe Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 471. Rest of Europe Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 472. Rest of Europe Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 473. Rest of Europe Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 474. MEA Ocaliva Sales, by Country K Tons (2021-2026)
  • Table 475. MEA Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 476. MEA Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 477. MEA Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 478. MEA Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 479. Middle East Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 480. Middle East Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 481. Middle East Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 482. Middle East Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 483. Africa Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 484. Africa Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 485. Africa Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 486. Africa Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 487. North America Ocaliva Sales, by Country K Tons (2021-2026)
  • Table 488. North America Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 489. North America Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 490. North America Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 491. North America Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 492. United States Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 493. United States Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 494. United States Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 495. United States Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 496. Canada Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 497. Canada Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 498. Canada Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 499. Canada Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 500. Mexico Ocaliva Sales, by Application K Tons (2021-2026)
  • Table 501. Mexico Ocaliva Sales, by Distribution Channel K Tons (2021-2026)
  • Table 502. Mexico Ocaliva Sales, by End-User K Tons (2021-2026)
  • Table 503. Mexico Ocaliva Sales, by Strength K Tons (2021-2026)
  • Table 504. Research Programs/Design for This Report
  • Table 505. Key Data Information from Secondary Sources
  • Table 506. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ocaliva: by Application USD Million (2015-2020)
  • Figure 5. Global Ocaliva: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Ocaliva: by End-User USD Million (2015-2020)
  • Figure 7. Global Ocaliva: by Strength USD Million (2015-2020)
  • Figure 8. South America Ocaliva Share (%), by Country
  • Figure 9. Asia Pacific Ocaliva Share (%), by Country
  • Figure 10. Europe Ocaliva Share (%), by Country
  • Figure 11. MEA Ocaliva Share (%), by Country
  • Figure 12. North America Ocaliva Share (%), by Country
  • Figure 13. Global Ocaliva: by Application K Tons (2015-2020)
  • Figure 14. Global Ocaliva: by Distribution Channel K Tons (2015-2020)
  • Figure 15. Global Ocaliva: by End-User K Tons (2015-2020)
  • Figure 16. Global Ocaliva: by Strength K Tons (2015-2020)
  • Figure 17. South America Ocaliva Share (%), by Country
  • Figure 18. Asia Pacific Ocaliva Share (%), by Country
  • Figure 19. Europe Ocaliva Share (%), by Country
  • Figure 20. MEA Ocaliva Share (%), by Country
  • Figure 21. North America Ocaliva Share (%), by Country
  • Figure 22. Global Ocaliva share by Players 2020 (%)
  • Figure 23. Global Ocaliva share by Players (Top 3) 2020(%)
  • Figure 24. Global Ocaliva share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 27. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 28. Intercept Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Intercept Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 30. Dainippon Sumitomo Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Dainippon Sumitomo Pharma (Japan) Revenue: by Geography 2020
  • Figure 32. Biophore India Pharmaceuticals Pvt (India) Revenue, Net Income and Gross profit
  • Figure 33. Biophore India Pharmaceuticals Pvt (India) Revenue: by Geography 2020
  • Figure 34. Summit Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Summit Pharmaceuticals (Japan) Revenue: by Geography 2020
  • Figure 36. Optimus Pharma P Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Optimus Pharma P Limited (India) Revenue: by Geography 2020
  • Figure 38. Alembic Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. Alembic Pharmaceuticals Limited (India) Revenue: by Geography 2020
  • Figure 40. MSN Laboratories Pvt Ltd (India) Revenue, Net Income and Gross profit
  • Figure 41. MSN Laboratories Pvt Ltd (India) Revenue: by Geography 2020
  • Figure 42. Sichuan Xieli Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 43. Sichuan Xieli Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 44. Changzhou Pharmaceutical Factory (China) Revenue, Net Income and Gross profit
  • Figure 45. Changzhou Pharmaceutical Factory (China) Revenue: by Geography 2020
  • Figure 46. Omgene Life Sciences (India) Revenue, Net Income and Gross profit
  • Figure 47. Omgene Life Sciences (India) Revenue: by Geography 2020
  • Figure 48. Global Ocaliva: by Application USD Million (2021-2026)
  • Figure 49. Global Ocaliva: by Distribution Channel USD Million (2021-2026)
  • Figure 50. Global Ocaliva: by End-User USD Million (2021-2026)
  • Figure 51. Global Ocaliva: by Strength USD Million (2021-2026)
  • Figure 52. South America Ocaliva Share (%), by Country
  • Figure 53. Asia Pacific Ocaliva Share (%), by Country
  • Figure 54. Europe Ocaliva Share (%), by Country
  • Figure 55. MEA Ocaliva Share (%), by Country
  • Figure 56. North America Ocaliva Share (%), by Country
  • Figure 57. Global Ocaliva: by Application K Tons (2021-2026)
  • Figure 58. Global Ocaliva: by Distribution Channel K Tons (2021-2026)
  • Figure 59. Global Ocaliva: by End-User K Tons (2021-2026)
  • Figure 60. Global Ocaliva: by Strength K Tons (2021-2026)
  • Figure 61. South America Ocaliva Share (%), by Country
  • Figure 62. Asia Pacific Ocaliva Share (%), by Country
  • Figure 63. Europe Ocaliva Share (%), by Country
  • Figure 64. MEA Ocaliva Share (%), by Country
  • Figure 65. North America Ocaliva Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Dr. Reddy's Laboratories (India)
  • Intercept Pharmaceuticals (United States)
  • Dainippon Sumitomo Pharma (Japan)
  • Biophore India Pharmaceuticals Pvt (India)
  • Summit Pharmaceuticals (Japan)
  • Optimus Pharma P Limited (India)
  • Alembic Pharmaceuticals Limited (India)
  • MSN Laboratories Pvt Ltd (India)
  • Sichuan Xieli Pharmaceutical (China)
  • Changzhou Pharmaceutical Factory (China)
  • Omgene Life Sciences (India)
Select User Access Type

Key Highlights of Report


May 2021 241 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ocaliva Market Quantitative research analysis
Global Ocaliva Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Ocaliva market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Ocaliva market are Dr. Reddy's Laboratories (India), Intercept Pharmaceuticals (United States), Dainippon Sumitomo Pharma (Japan), Biophore India Pharmaceuticals Pvt (India), Summit Pharmaceuticals (Japan), Optimus Pharma P Limited (India), Alembic Pharmaceuticals Limited (India), MSN Laboratories Pvt Ltd (India), Sichuan Xieli Pharmaceutical (China), Changzhou Pharmaceutical Factory (China) and Omgene Life Sciences (India), to name a few.
In this highly competitive & fast evolving Ocaliva industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Ocaliva Market Report?

Have a Query? Click Here

Other Related Reports

Lithium Medication Comprehensive Study by Type (Tablets, Capsules, Oral Solution), Application (Hospitals, Clinics, Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Online, Others...
$ 3500
Dietary Supplements Ingredients Comprehensive Study by Type (Andarine, Higenamine, Octopamine, Sodium Tetrachloroaurate, Cesium Chloride, Others), Application (Additional Supplements, Medicinal Suppl...
$ 3450
Glatiramer Comprehensive Study by Type (Brand Medicine, Generic Drug), Application (Hospital, Pharmacy, Other), Route of Administration (Enteral Route, Parenteral Route), Intake Form (Alone, With Oth...
$ 3500
Metformin Drugs Comprehensive Study by Type (Metformin-Alogliptin, Metformin-Canagliflozin, Metformin-Dapagliflozin, Metformin-Empagliflozin, Others), Category (Immediate Release, Extended Release), ...
$ 3650
Anlotinib Drugs Comprehensive Study by Application (Hospital, Drug Store, Other), Distribution Channel (Online, Offline), End-User (Adult, Paediatric), Strength (8 mg, 10 mg, 12 mg) Players and Regio...
$ 3500
Osimertinib Comprehensive Study by Application (Cancer Clinics, Hospitals, Research Institutions), Distribution Channel (Online, Offline), End-User (Men, Women), Strength (40 mg, 80 mg)
$ 3500